TY - JOUR
T1 - Carfilzomib-induced thrombotic microangiopathy (TMA)
T2 - an under-recognised spectrum of disease from microangiopathic haemolysis to subclinical TMA
AU - Ponraj, Royston
AU - Bryant, Adam
AU - Dunlop, Lindsay
AU - Range, Heather
AU - Cobrador, Cherry
AU - Ling, Silvia
AU - Hsu, Danny
PY - 2023/7
Y1 - 2023/7
N2 - Carfilzomib is an effective therapy for multiple myeloma. However, carfilzomib-induced thrombotic microangiopathy (TMA) has emerged as a potential severe complication, characterised by microangiopathic haemolytic anaemia (MAHA) together with end organ damage, particularly kidney injury.
AB - Carfilzomib is an effective therapy for multiple myeloma. However, carfilzomib-induced thrombotic microangiopathy (TMA) has emerged as a potential severe complication, characterised by microangiopathic haemolytic anaemia (MAHA) together with end organ damage, particularly kidney injury.
UR - http://www.scopus.com/inward/record.url?scp=85165686675&partnerID=8YFLogxK
U2 - 10.1038/s41408-023-00885-9
DO - 10.1038/s41408-023-00885-9
M3 - Article
C2 - 37495597
AN - SCOPUS:85165686675
SN - 2044-5385
VL - 13
JO - Blood Cancer Journal
JF - Blood Cancer Journal
IS - 1
M1 - 113
ER -